AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02577523
Drug: ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The total daily dose levodopa/carbidopa from ND0612 538/67 mg. Morning dose of oral IR-LD/CD 150/15 mg. Device: CRONO TWIN pump system.
Trial: NCT02987465
Drug: BQ 123
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BQ 123 is being used as a challenge agent in this study and is an (Endothelin A) ETA receptor agonist.
Trial: NCT03138421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00911066
Drug: MLN4924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN4924 intravenous (IV) on a 21-day cycle on one of the following schedules:~* Days 1, 3, and 5, followed by a rest period of 16 days (Schedule A)~* Days 1, 4, 8, and 11, followed by a rest period of 10 days (Schedule B)~* Continuous weekly dosing on Days 1, 8, and 15 (Schedule C)~* Days 1, 4, 11, 15 for Cycle 1 only; Days 1, 4, 8, 11 for all subsequent cycles (Schedule D)~* Dosing on Days 1, 3, and 5 in patients with high-grade MDS or AML (Schedule E)
Trial: NCT01380769
Drug: CRLX101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRLX101 is administered at 15mg/m2 IV every other week
Trial: NCT02757144
Drug: DWP14012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 tablets
Trial: NCT02757144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets
Trial: NCT04039958
Drug: Soviredia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
Trial: NCT04095182
Drug: Placebo for Zebinix 400mg
RxNorm normalized name: placebo 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Zebinix 400mg group is administered with two placebo for Zebinix 200mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)
Trial: NCT04095182
Drug: Placebo for Zebinix 800mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Zebinix 800mg group is administered with a placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)
Trial: NCT04095182
Drug: Placebo for Zebinix 1600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Zebinix 1600mg group is administered with two placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5\~11)
Trial: NCT01391624
Drug: Paraffin + # 2 dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules of mineral oil (ineffective) for 8 weeks.
Trial: NCT03499184
Drug: Amoxil 500 mg Oral Capsule
RxNorm normalized name: Amoxil 500 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemically administered Amoxil 500 mg thrice daily
Trial: NCT00644150
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If an STI is confirmed by a lab test, participants will receive standard of care treatment. Gonorrhea will be treated with a single dose of 250 mg of ceftriaxone sodium administered by intramuscular injection. If patients are allergic to ceftriaxone, they will be treated with azithromycin (2 g single oral dose). Chlamydia will be treated with azithromycin (1 g single oral dose).
Trial: NCT02384928
Drug: Conventional medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics. The most frequently prescribed conventional drugs for LDH include aceclofenac (Drug class: nonsteroidal antiinflammatoy drugs (NSAIDs)), tramadol hydrochloride (Drug class: Opioids), talniflumate (Drug class: NSAIDs), diclofenac sodium (Drug class: NSAIDs), and loxoprofen sodium (Drug class: NSAIDs).
Trial: NCT03400852
Drug: MNK-1411
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNK-1411 (1 mg/mL suspension) for subcutaneous injection
Trial: NCT02241668
Drug: 3'-Deoxy-3'-18f-Fluorothymidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3'-Deoxy-3'-18f-Fluorothymidine solution injected through a central venous catheter after MRI scan. After solution injected into a vein, PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. Entire procedure should last about 60-70 minutes.
Trial: NCT00950404
Drug: Formulation B ODT tablet 50 mg
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral disintegrating tablet (ODT), 50 mg, single dose administered without water
Trial: NCT00950404
Drug: Formulation C ODT tablet 50 mg
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ODT, 50 mg, single dose administered without water
Trial: NCT00950404
Drug: Formulation D ODT tablet 50 mg
RxNorm normalized name: Rho(D) Unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ODT, 50 mg, single dose, administered without water
Trial: NCT00531518
Drug: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, daily, generally at lower than manufacturer's recommendations
Trial: NCT03921450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Hz stimulation with the placebo TMS coil without any magnetic emission
Trial: NCT00545090
Drug: ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg po monthly for 6 months
Trial: NCT00721448
Drug: AZD6140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90mg tablet, oral, once daily for the first day and twice daily from day 4 to 9
Trial: NCT00721448
Drug: AZD6140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 x 2 mg tablets, oral, once daily for the first day and twice daily from day 4 to 9
Trial: NCT02925000
Drug: TLC178
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC178
Trial: NCT00736450
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00736450
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00680342
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700mg dose (5 pills, three times daily) for 24-week treatment period
Trial: NCT00680342
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 420mg dose (5 pills, three times daily) for 24-week treatment period
Trial: NCT00078572
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2 and for the combination arm was 2000 mg/m2.
Trial: NCT00790192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo to Lurasidone or Quetiapine
Trial: NCT04282668
Drug: TAS1440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: Capsule or Tablet Route of Administration: Oral
Trial: NCT00332644
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage same as active drug conditions
Trial: NCT00255281
Drug: AZD7009, no generic name available
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02104648
Drug: RO4602522
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, oral dose
Trial: NCT02935530
Drug: LMWH
RxNorm normalized name: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4250KU, subcutaneous injection of 5-10 days
Trial: NCT00250237
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1mg twice daily during 72hours
Trial: NCT01616654
Drug: CD5789 25 µg/g cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD5789 25 µg/g cream applied once daily
Trial: NCT01616654
Drug: CD5789 50 µg/g cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD5789 50 µg/g cream applied once daily
Trial: NCT01616654
Drug: CD5789 100 µg/g cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD5789 100 µg/g cream applied once daily
Trial: NCT01616654
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream applied once daily
Trial: NCT02817217
Drug: SP2086
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP2086 will be administered orally (by mouth) as 100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
Trial: NCT00606580
Drug: WR 279,396 topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WR 279,396 is a topical antibiotic cream containing 15% paromomycin and 0.5% gentamicin that will be applied to each lesion once a day and covered with a sterile gauze and tape dressing.
Trial: NCT00606580
Drug: Paromomycin Alone topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The antibiotic paromomycin 15% in the same topical cream used in arm 1 will be applied to lesions daily and covered with a protective sterile gauze and tape dressing.
Trial: NCT00606580
Drug: Vehicle placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied daily to cutaneous leishmaniasis lesions, primarily ulcerative, and covered with a protective, sterile gauze and tape dressing.
Trial: NCT02169154
Drug: 1% Diclofenac Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% diclofenac sodium
Trial: NCT02493036
Drug: SYN-010
RxNorm normalized name: Gel-Syn
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01645254
Drug: Argemone mexicana
RxNorm normalized name: ARGEMONE MEXICANA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30g, the powder decoction 2 times a day for 14 days
Trial: NCT02169154
Drug: 0.9% Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Saline
Trial: NCT03983889
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
Trial: NCT03983889
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
Trial: NCT00923676
Drug: fenofibrate + rosuvastatin
RxNorm normalized name: rosuvastatin and fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenofibrate 145 mg/day + rosuvastatin 10 mg/day for 12 months
Trial: NCT02303444
Drug: Other Multikinase inhibitors
RxNorm normalized name: ACE inhibitors, other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients can get MKIs at any time during study.
Trial: NCT05719818
Drug: biphosphonates
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of bisphosphonate therapy
Trial: NCT01468740
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain doxorubicin.~* Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.
Trial: NCT00159354
Drug: predisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05329454
Drug: Ibuprofen Tablets
RxNorm normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment A:~One tablet of IBUMR will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBUMR every 12 hours for a total of 7 doses.~Treatment B:~One tablet of IBURed will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBURed every 8 hours for a total of 10 doses.~Treatment C:~Single dose of IBUMR will be given to the subjects under fed condition (a standard high-fat, high calorie breakfast should be consumed within 30 minutes prior to dosing).
Trial: NCT03646006
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL normal saline
Trial: NCT02734628
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Bepanthen® ointment without active ingredient dexpanthenol
Trial: NCT01468740
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The seven-drug BEACOPP-baseline chemotherapy regimen contains cyclophosphamide.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.
Trial: NCT03608618
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous administration for preconditioning
Trial: NCT00612586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, daily (up to 1 yr or until progressive disease)
Trial: NCT00612586
Drug: Leucovorin (LV)
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 milligram per meter squared (mg/m\^2) intravenously (IV), Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
Trial: NCT00542087
Drug: MK0663, etoricoxib / Duration of Treatment: 6 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00542087
Drug: Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00750750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
Trial: NCT00624312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days prior to surgery - injection with 60,000 IU of placebo~Day of surgery - injection with 60,000 IU of placebo
Trial: NCT00988078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule (without biologic action) administered three times a day for six months
Trial: NCT00949975
Drug: AZD9668
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 30 mg oral tablets twice daily (bid) for 12 weeks
Trial: NCT00949975
Drug: AZD9668
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 10 mg oral tablets twice daily (bid) for 12 weeks
Trial: NCT00949975
Drug: AZD9668
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks
Trial: NCT00949975
Drug: AZD9668 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks
Trial: NCT00922207
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From week -4 to week 2
Trial: NCT02311907
Drug: Glutathione
RxNorm normalized name: Glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV, over 15 minutes, immediately before chemotherapy administration
Trial: NCT03969472
Drug: probiotics
RxNorm normalized name: probiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apply probiotic after operation
Trial: NCT00491517
Drug: conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drugs for patients with high blood pressure.
Trial: NCT01677325
Drug: Chinese herb (YiQiSanJu)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herb formula:Huangqi,huanglian,yinchen,ect
Trial: NCT01553721
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase IIa - placebo Phase IIb - placebo
Trial: NCT01312441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by mouth once weekly for 6 months
Trial: NCT00166166
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-arterial infusion of acetylcholine at 7.5, 15 and 30 μg/min. Each dose will be given for 5 minutes.
Trial: NCT03699293
Drug: celecoxib 200mg capsule
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: celecoxib 200mg twice a day for 4 weeks
Trial: NCT03699293
Drug: naproxen sodium 550mg tablet
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen sodium 550mg twice a day for 4 weeks
Trial: NCT00988637
Drug: Vectical™ Ointment weekdays and Clobex® Spray weekends regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vectical™ Ointment 3 µg/g, topical, apply twice daily on weekdays (Mon-Fri) and Clobex® Spray 0.05% twice daily on weekends (Sat-Sun) for 28 days
Trial: NCT00988637
Drug: Clobex® Spray morning and Vectical™ Ointment evening regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobex® Spray 0.05%, topical, apply once each morning and Vectical™ Ointment 3 µg/g, topical, apply once each evening for 28 days
Trial: NCT04677322
Drug: Adult patients diagnosed and treated for high blood pressure
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational program interventions conducted by primary care staff to encourage adherence to a low-sodium diet consisting of direct action on the patient and provision of educational materials will be assessed. Compliance and follow-up of the low sodium diet will be done by monitoring the sodium in urine in the target population, selected according to the selection criteria described in the protocol.
Trial: NCT02052375
Drug: ASP2408
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT02052375
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT02794766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 gum each 12 hours for 10 days
Trial: NCT04191486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: NCT00647530
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00647530
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03035045
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03762031
Drug: GC4711 30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose given via a 15 minute intravenous infusion
Trial: NCT03762031
Drug: GC4711 60mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose given via a 15 minute intravenous infusion
Trial: NCT03762031
Drug: GC4711 90mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose given via a 15 minute intravenous infusion
Trial: NCT03762031
Drug: GC4711 120mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose given via a 15 minute intravenous infusion
Trial: NCT03762031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of normal saline given via a 15 minute intravenous infusion
Trial: NCT03762031
Drug: GC4711 75mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose given via a 15 minute intravenous infusion
Trial: NCT03762031
Drug: GC4711 105mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose given via a 15 minute intravenous infusion
Trial: NCT04626375
Drug: Bioarginine
RxNorm normalized name: Tilarginine
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the Bioarginine group the partecipants take bioarginine (2 vials per os of 1.66 g every 12 hours) for 4 week
Trial: NCT04626375
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the Placebo group the participants take bio-arginine (2 vials per os of 1.66 g every 12 hours) for 4 week
Trial: NCT02884544
Drug: HLD100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment
Trial: NCT02008084
Drug: TRIA-662
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following Baseline randomized to active TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then active TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.